Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: A comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening

Cancer

Volumn 83, Issue 8, 1998, Pages 1626-1633

  Tanaka, Takeo ^a   Sugimoto, Tohru ^b   Sawada, Tadashi ^c  

^a National Kure Hospital   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Ha ras; Immunohistochemistry; Mass screening; N myc; Neuroblastoma; Prognostic factors; Trk A

Indexed keywords

ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SCREENING; NEUROBLASTOMA; ONCOGENE; ONCOGENE H RAS; PRIORITY JOURNAL; PROGNOSIS;

AGE FACTORS; BIOLOGY; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FORECASTING; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MASS SCREENING; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUROBLASTOMA; ONCOGENES; PATIENT CARE PLANNING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 0032531963     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981015)83:8<1626::AID-CNCR19>3.0.CO;2-Y     Document Type: Article

References (38)

1. Tonini GP. Neuroblastoma: a multiple biological disease. Eur J Cancer 1993;29A:802-4.
2. Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 1992;14:111-6.
3. Carlsen NTL. Neuroblastomas in Denmark 1943-80: epidemiological and clinical studies. Acta Paediatr 1994;83(Suppl 403):1-26.
4. Sawaguchi S, Kaneko M, Uchino J, Takeda T, Iwafuchi M, Matsuyama S, et al. Treatment of advanced neuroblastom1a with emphasis on intensive induction chemotherapy: a report from the study group of Japan. Cancer 1990;66:1879-87.
5. De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, et al. Disseminated neuroblastoma (Stage IV and IVs) in the first year of life. Cancer 1992;70:1625-33.
6. Joshi W, Cantor AB, Altshuler G, Larkin EW, Neill JS, Shuster JJ, et al. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas: a clinicopathologic study of 211 cases from the pediatric oncology group. Cancer 1992;69:2197-211.
7. Paul SR, Tarbell NJ, Korf B, Kretschmar CS, Lavally B, Grier HE. Stage IVs neuroblastoma in infants: Long term survival. Cancer 1991;67:1493-97.
8. Haas D, Ablin AR, Miller C, Zoger S, Matthay K. Complete pathologic maturation and regression of stage IVs neuroblastoma without treatment. Cancer 1988;62:818-25.
9. Sawada T, Sugimoto T, Tanaka T, Kawakatsu H, Ishii T, Matsumura T, et al. Number and cure rate of neuroblastoma cases detected by the mass-screening program in Japan: future aspects. Med Pediatr Oncol 1987;15:14-7.
10. Sawada T, Nagahara N, Yamamoto K, Okabe I, Hanawa Y, Hashizume K, et al. Mass screening for neuroblastoma in Japan. Acta Paediatr Jpn 1990;32:725-33.
11. Nishi M, Miyake H, Takeda T, Kikuchi Y, Hanai J, Yonemori H, et al. Mass screening of neuroblastoma in Sapporo City, Japan. Am J Pediatr Hematol Oncol 1992;14:327-31.
12. Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 1992;14:111-6.
13. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SW, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
14. Brodeur GM, Green AA, Hayes FA, Williams KJ, Tsiatis AA. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 1981;41:4678-86.
15. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-5.
16. Tanaka T, Slamon DJ, Shimoda H, Waki C, Kawaguchi Y, Tanaka Y, et al. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res 1988;48: 1030-4.
17. Tanaka T, Slamon DJ, Shimada H, Shimoda H, Fujisawa T, Ida N, et al. A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis: a retrospective study of 103 cases. Cancer 1991;68:1296-302.
18. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Canter AB, Brodeur GM. Association between high levels of expression of the trk gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54.
19. Tanaka T, Hiyama E, Sugimoto T, Sawada T, Tanabe M, Ida N. trk A gene expression in neuroblastoma: the clinical significance of an immunohistochemical study. Cancer 1995;76:1086-95.
20. Evans AE, D'Angio GJ, Randolph JA. A proposed staging for children with neuroblastoma. Cancer 1971;27:374-8.
21. Thomas SM, DeMarco M, D'Arcangelo G, Halegoua S, Brugge JS. ras is essential for nerve growth factor- and phorbolester-induced tyrosine phosphorylation of MAP kinases. Cell 1992;68:1031-40.
22. Wood KW, Sarnechi C, Roberts TM, Blenis J. ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell 1992;68:1041-50.
23. Li BQ, Kaplan D, Kung H, Kamata T. Nerve growth factor stimulation of the ras-guanin nucleotide exchange factor and GAP activities. Science 1992;256:1456-9.
24. Ragsdale C, Woodgett J. Trking neurotropic receptors. Nature 1991;350:660-1.
25. Bothwell M. Keeping track of neurotropin receptors. Cell 1991;65:915-8.
26. Martin-Zanca D, Barbacid M, Parada LF. Expression of the trk protooncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development. Genes Dev 1990;4:683-94.
27. Satoh T, Nakafuku M, Kaziro Y. Function of ras as a molecular switch in signal transduction. J Biol Chem 1992; 267: 24149-52.
28. Tanaka T, Ida N, Shimoda H, Waki C, Slamon DJ, Cline MJ. Organ specific expression of ras oncoproteins during growth and development of the rat. Mol Cell Biochem 1986;70:97-104.
29. Tanaka T, Ida N, Waki C, Shimoda H, Slamon DJ, Cline MJ. Cell type specific expression of c-ras oncogene products in normal rat. Mol Cell Biochem 1987;75:23-35.
30. Noda M, Ko M, Liu D, Amano T, Takano T, Ikawa Y. Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in neural cell line. Nature 1985;318:73-5.
31. Bar-Sagi D, Feramisco JR. Microinjection of the ras oncogene protein into PC12 cells induce morphological differentiation. Cell 1985;42:841-8.
32. Hagag N, Halegoua S, Viola M. Inhibition of growth factor-induced differentiation of PC12 cells by microinjection of antibody to ras p21. Nature 1986;319:680-2.
33. Satoh T, Nakamura S, Kaziro Y. Induction of neurite formation in PC12 cells by microinjection of protooncogenic Haras protein preincubated with guanosine-5′-o-(3-thiotriphosphate). Mol Cell Biol 1987;7:4553-6.
34. Sawada T and the Committee on Neuroblastoma MassScreening of the Japanese Childhood Cancer Research. Annual registration of the neuroblastoma cases detected by a mass-screening program [in Japanese). Jpn J Pediatr Oncol 1996;33:278-83.
35. Nishi M, Miyake H, Takeda T, Yonemori H, Hanai J, Kikuchi Y, et al. Cases of spontaneous regression and true patients detected in mass screening for neuroblastoma. Int J Pediatr Hematol Oncol 1995;1:557-63.
36. Tanaka T, Tanabe M, Sugimoto T, Ida N, Sawada T. Agerelated profile of neuroblastoma: a comparison of tumors detected by mass-screening with those detected clinically. Acta Paediatr Jpn 1995;37:154-9.
37. Kerbl R, Urban CE, Lackner H, Hofler G, Ambros IM, Rutschek M, et al. Connatal localized neuroblastoma: the case to delay treatment. Cancer 1996;77:1395-401.
38. Hiraiwa H, Hamazaki M, Takata A, Kikuchi H, Hata J. A neuroblastoma cell line derived from a case detected through a mass screening system in Japan: a case report including the biologic and phenotypic characteristics of the cell line. Cancer 1997;79:2036-44.